2 weeks Ago By Defense World Staff
Biomea Fusion, Inc. ( NASDAQ:BMEA – Get Free Report ) Director Michael J.M.
Hitchcock acquired 10,000 shares of Biomea Fusion stock in a transaction dated Monday, September 30th. The stock was purchased at an average cost of $10.06 per share, with a total value of $100,600.
00. Following the completion of the purchase, the director now owns 15,000 shares of the company’s stock, valued at $150,900. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink .
Biomea Fusion Stock Down 5.9 % Biomea Fusion stock traded down $0.60 during mid-day trading on Tuesday, reaching $9.
50. 902,217 shares of the company’s stock traded hands, compared to its average volume of 1,052,377. Biomea Fusion, Inc.
has a 12-month low of $3.61 and a 12-month high of $22.74.
The stock has a 50 day moving average of $6.99 and a two-hundred day moving average of $8.85.
The company has a market cap of $341.48 million, a price-to-earnings ratio of -2.61 and a beta of -0.
47. Biomea Fusion ( NASDAQ:BMEA – Get Free Report ) last announced its earnings results on Wednesday, July 31st. The company reported ($1.
03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.03). As a group, sell-side analysts forecast that Biomea Fusion, Inc.
will post -4.09 earnings per share for the current year. Institutional Investors Weigh In On Biomea Fusion Analysts Set New Price Targets BMEA has been the subject of a number of analyst reports.
RODMAN&RENSHAW upgraded Biomea Fusion to a “strong-buy” rating in a research note on Thursday, September 26th. Citigroup decreased their target price on Biomea Fusion from $45.00 to $22.
00 and set a “buy” rating on the stock in a research note on Tuesday, August 27th. Scotiabank boosted their price target on Biomea Fusion from $21.00 to $41.
00 and gave the stock a “sector outperform” rating in a report on Friday. Piper Sandler cut their price objective on shares of Biomea Fusion from $45.00 to $10.
00 and set an “overweight” rating for the company in a report on Friday, June 7th. Finally, Barclays lifted their price objective on shares of Biomea Fusion from $5.00 to $9.
00 and gave the company an “equal weight” rating in a research report on Friday. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.
com, Biomea Fusion currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.40. View Our Latest Stock Analysis on Biomea Fusion Biomea Fusion Company Profile ( Get Free Report ) Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases.
Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. See Also Five stocks we like better than Biomea Fusion Industrial Products Stocks Investing Why Lennar Stock Could Be the Best Play in the Housing Market What Are Dividend Champions? How to Invest in the Champions 2 Energy Stocks Fueling the AI Datacenter Boom What Do S&P 500 Stocks Tell Investors About the Market? Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech? Receive News & Ratings for Biomea Fusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomea Fusion and related companies with MarketBeat.com's FREE daily email newsletter .
.
